Skip to content

Study · Randomized controlled trial · n = 38 · 2005

3 results

Bone mineral and collagen quality in iliac crest biopsies of patients given teriparatide: new results from the fracture prevention trial.

Paschalis EP, Glass EV, Donley DW, Eriksen EF

The Journal of clinical endocrinology and metabolism24 May 2005Cited by 107 (Europe PMC)

PMID15914535 (opens in a new tab)DOI10.1210/jc.2004-2489 (opens in a new tab)PepBankPUB-15914535
Source linkPubMedAsk about this study
Jump to 3 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study3

3 results from studies that gave the peptide. 3 results from people.

  1. 01HumanRandomized controlled trialEfficacy outcome

    In women with osteoporosis, teriparatide at both doses significantly lowered bone matrix mineralization versus placebo.

    In plain wordsIn women with osteoporosis, both teriparatide doses lowered bone matrix mineralization versus placebo.

    Peptide
    Teriparatide (PTH 1-34)
    Outcome
    DecreaseMatrix mineralization
    Study

    n = 38

    Comparator
    Placebo
    Outcome group
    Bone and joint · Musculoskeletal
    Studied dose
    20 and 40 microg daily · subcutaneous · 12 months or end of treatment at 19-24 monthsAs given in this study (human).

    Source sentences

    Summary
    Patients administered teriparatide 20 and 40 microg/d exhibited significantly lower matrix mineralization, mineral crystallinity, and collagen cross-link ratio when compared with placebo.
    4 context sentences
    Summary · context
    The Fracture Prevention Trial was randomized, double blind, and placebo-controlled.
    Summary · context
    Patients consisted of postmenopausal women with osteoporosis.
    Summary · context
    Patients were randomized to receive daily sc injections of placebo (n = 12) or 20 microg (n = 13) or 40 microg (n = 13) teriparatide.
    Summary · context
    Biopsies were obtained after 12 months of treatment or at the end of treatment (range, 19-24 months for end of treatment paired biopsies).
  2. 02HumanRandomized controlled trialEfficacy outcome

    In women with osteoporosis, teriparatide at both doses significantly lowered bone mineral crystallinity versus placebo.

    In plain wordsIn women with osteoporosis, both teriparatide doses lowered bone mineral crystallinity versus placebo.

    Peptide
    Teriparatide (PTH 1-34)
    Outcome
    DecreaseMineral crystallinity
    Study

    n = 38

    Comparator
    Placebo
    Outcome group
    Bone and joint · Musculoskeletal
    Studied dose
    20 and 40 microg daily · subcutaneous · 12 months or end of treatment at 19-24 monthsAs given in this study (human).

    Source sentences

    Summary
    Patients administered teriparatide 20 and 40 microg/d exhibited significantly lower matrix mineralization, mineral crystallinity, and collagen cross-link ratio when compared with placebo.
    4 context sentences
    Summary · context
    The Fracture Prevention Trial was randomized, double blind, and placebo-controlled.
    Summary · context
    Patients consisted of postmenopausal women with osteoporosis.
    Summary · context
    Patients were randomized to receive daily sc injections of placebo (n = 12) or 20 microg (n = 13) or 40 microg (n = 13) teriparatide.
    Summary · context
    Biopsies were obtained after 12 months of treatment or at the end of treatment (range, 19-24 months for end of treatment paired biopsies).
  3. 03HumanRandomized controlled trialEfficacy outcome

    In women with osteoporosis, teriparatide at both doses significantly lowered collagen cross-link ratio versus placebo.

    In plain wordsIn women with osteoporosis, both teriparatide doses lowered the collagen cross-link ratio versus placebo.

    Peptide
    Teriparatide (PTH 1-34)
    Outcome
    DecreaseCollagen cross-link ratio
    Study

    n = 38

    Comparator
    Placebo
    Outcome group
    Bone and joint · Musculoskeletal
    Studied dose
    20 and 40 microg daily · subcutaneous · 12 months or end of treatment at 19-24 monthsAs given in this study (human).

    Source sentences

    Summary
    Patients administered teriparatide 20 and 40 microg/d exhibited significantly lower matrix mineralization, mineral crystallinity, and collagen cross-link ratio when compared with placebo.
    4 context sentences
    Summary · context
    The Fracture Prevention Trial was randomized, double blind, and placebo-controlled.
    Summary · context
    Patients consisted of postmenopausal women with osteoporosis.
    Summary · context
    Patients were randomized to receive daily sc injections of placebo (n = 12) or 20 microg (n = 13) or 40 microg (n = 13) teriparatide.
    Summary · context
    Biopsies were obtained after 12 months of treatment or at the end of treatment (range, 19-24 months for end of treatment paired biopsies).

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    22 Oct 2026, 02:26 UTC

    Study results updated

  2. Version 1

    21 Oct 2026, 18:59 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.